Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics to Sell $17.5M in Common Stock Through Direct Offering

NEW YORK — Cancer Genetics said on Wednesday that it has signed agreements to sell roughly $17.5 million of its common stock to unnamed institutional investors.

According to the Rutherford, New Jersey-based cancer drug-discovery services provider, it will issue approximately 2.7 million shares of stock at $6.30 apiece in a registered direct offering priced at-the-market under Nasdaq rules. It expects the offering, which is being underwritten by HC Wainwright, to close early next week.

Cancer Genetics said it will use the proceeds for general corporate purposes, including working capital and capital expenditures. The proceeds are expected to be available following the company's planned merger with Stemonix. 

Earlier this year, Cancer Genetics signed agreements to sell $10 million in stock and warrants to institutional and accredited investors. 

During mid-morning trading on the Nasdaq, shares of Cancer Genetics were down 19 percent at $6.95.

 

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.